JP2025513345A5 - - Google Patents

Info

Publication number
JP2025513345A5
JP2025513345A5 JP2024561810A JP2024561810A JP2025513345A5 JP 2025513345 A5 JP2025513345 A5 JP 2025513345A5 JP 2024561810 A JP2024561810 A JP 2024561810A JP 2024561810 A JP2024561810 A JP 2024561810A JP 2025513345 A5 JP2025513345 A5 JP 2025513345A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glp
exendin
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2023/005198 external-priority patent/WO2023204556A1/ko
Publication of JP2025513345A publication Critical patent/JP2025513345A/ja
Publication of JP2025513345A5 publication Critical patent/JP2025513345A5/ja
Pending legal-status Critical Current

Links

JP2024561810A 2022-04-18 2023-04-18 腸疾患の予防又は治療のためのGLP-2と、インスリン分泌ペプチド、TNFα抑制剤、又はその両方の併用療法 Pending JP2025513345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20220047662 2022-04-18
KR10-2022-0047662 2022-04-18
PCT/KR2023/005198 WO2023204556A1 (ko) 2022-04-18 2023-04-18 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법

Publications (2)

Publication Number Publication Date
JP2025513345A JP2025513345A (ja) 2025-04-24
JP2025513345A5 true JP2025513345A5 (cg-RX-API-DMAC7.html) 2026-04-27

Family

ID=88420096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561810A Pending JP2025513345A (ja) 2022-04-18 2023-04-18 腸疾患の予防又は治療のためのGLP-2と、インスリン分泌ペプチド、TNFα抑制剤、又はその両方の併用療法

Country Status (10)

Country Link
US (1) US20250276044A1 (cg-RX-API-DMAC7.html)
EP (1) EP4512414A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025513345A (cg-RX-API-DMAC7.html)
KR (1) KR20230149258A (cg-RX-API-DMAC7.html)
CN (1) CN119325387A (cg-RX-API-DMAC7.html)
AU (1) AU2023256431A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249442A1 (cg-RX-API-DMAC7.html)
IL (1) IL316444A (cg-RX-API-DMAC7.html)
MX (1) MX2024012860A (cg-RX-API-DMAC7.html)
WO (1) WO2023204556A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP2376097A4 (en) * 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
WO2016066818A1 (en) * 2014-10-31 2016-05-06 Gubra Aps Compositions and peptides having dual glp-1r and glp-2r agonist activity
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
AR113258A1 (es) * 2017-09-28 2020-03-11 Hanmi Pharm Ind Co Ltd Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
US20230110689A1 (en) * 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome

Similar Documents

Publication Publication Date Title
KR102310389B1 (ko) Gip-glp-1 이원 효능제 화합물 및 방법
KR102311517B1 (ko) 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
JP5683951B2 (ja) 長期間作用性ペプチド類似体のための組成物
CN107129538B (zh) Glp-1受体激动剂和胃泌素的肽缀合物及其用途
AU2015242657B2 (en) Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
JP2014141500A (ja) グルカゴン/glp−1受容体コアゴニスト
JP2018162298A (ja) オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
CN110099692A (zh) 作为神经肽y受体调节剂的环状肽酪氨酸酪氨酸化合物
CA2732949A1 (en) Analogues of glucose-dependent insulinotropic polypeptide
BR122022025353B1 (pt) Composição e uso de conjugado de derivado de oxintomodulina para a prevenção ou tratamento de hiperlipidemia, doença hepática gordurosa ou arteriosclerose
CA2965560A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
CA2732973A1 (en) Glucose-dependent insulinotropic polypeptide analogues
JPWO2011052523A1 (ja) 抗原性glp−1アナログの糖鎖付加体
JP2022551233A (ja) 異なる構造のglp-1アナログペプチド修飾二量体およびその調製方法のii型糖尿病の治療における用途
JP2025525218A (ja) インクレチンアナログおよびその使用
JP2023525260A (ja) 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途
AU2016332062A1 (en) Treatment of bile acid disorders
WO2020098657A1 (zh) 具有双重受体激动作用的胰高血糖素衍生肽及其用途
JP2023538236A (ja) グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
KR20210116322A (ko) 신규 이중 특이성 단백질 및 그의 용도
WO2004048401A1 (ja) ペプチド及びこれを含む医薬組成物
RU2024132221A (ru) Комбинированная терапия, включающая GLP-2 с инсулинотропным пептидом, ингибитором TNFα или с ними обоими, для предупреждения или лечения
US20260028397A1 (en) Methods of treating ankylosing spondylitis
KR20220010462A (ko) 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
CN115776880A (zh) 液体制剂